ZFIN ID: ZDB-FISH-150901-3654
Fish name: y1Tg
Genotype: y1Tg
Targeting Reagent: none
HUMAN DISEASE MODELED by y1Tg
Human Disease Conditions Citations
oral squamous cell carcinoma cancer xenotransplantation Xiong et al., 2013
carcinoma cancer xenotransplantation Zimmerli et al., 2020
cancer xenotransplantation Varanda et al., 2020
colorectal cancer cancer xenotransplantation Paauwe et al., 2018
cancer xenotransplantation Oliveira et al., 2020
stomach cancer cancer xenotransplantation Wu et al., 2022
Zika fever xenotransplantation Ayala-Nunez et al., 2019
atherosclerosis physical alteration: intersegmental vessel, chemical treatment by injection: agarose Choi et al., 2017
pulmonary hypertension chemical treatment by environment: sodium nitroprusside Sasagawa et al., 2016
breast cancer cancer xenotransplantation Jia et al., 2016
cancer xenotransplantation Hung et al., 2016
cancer xenotransplantation Yang et al., 2020
lung cancer cancer xenotransplantation Shen et al., 2020
neuroendocrine tumor cancer xenotransplantation Gaudenzi et al., 2017
retinoblastoma cancer xenotransplantation Chen et al., 2015
squamous cell carcinoma cancer xenotransplantation Martins et al., 2015
cancer cancer xenotransplantation Gnosa et al., 2016
cancer xenotransplantation Mercatali et al., 2016
cancer xenotransplantation Vazquez Rodriguez et al., 2017
cancer xenotransplantation Hsieh et al., 2017
cancer xenotransplantation Yang et al., 2015
cancer xenotransplantation Liu et al., 2017
cancer xenotransplantation Aveic et al., 2017
cancer xenotransplantation Li et al., 2016
cancer xenotransplantation Weijts et al., 2017
cancer xenotransplantation Itou et al., 2017
cancer xenotransplantation CichoD et al., 2014
cancer xenotransplantation Fu et al., 2016
cancer xenotransplantation Wang et al., 2016
cancer xenotransplantation Yang et al., 2016
cancer xenotransplantation Stantic et al., 2015
cancer xenotransplantation Wu et al., 2017
cancer xenotransplantation Jung et al., 2012
cancer xenotransplantation Huang et al., 2017
cancer xenotransplantation Sonay et al., 2021
cancer xenotransplantation Würth et al., 2017
cancer xenotransplantation Baltrunaite et al., 2017
cancer xenotransplantation Palano et al., 2020
cancer xenotransplantation Vervoort et al., 2018
cancer xenotransplantation Fior et al., 2017
retinopathy of prematurity chemical treatment: GS4012 Wu et al., 2015
chemical treatment: cobalt dichloride Wu et al., 2015
glioblastoma cancer xenotransplantation Yang et al., 2013
cancer xenotransplantation Yang et al., 2014
cancer xenotransplantation Pudelko et al., 2018
colon cancer cancer xenotransplantation Basti et al., 2020
insulinoma cancer xenotransplantation Buishand et al., 2016
melanoma cancer xenotransplantation Franich et al., 2020
cancer xenotransplantation Gabellini et al., 2017
cancer xenotransplantation Evensen et al., 2016
cancer xenotransplantation Cao et al., 2020
hepatocellular carcinoma cancer xenotransplantation Tonon et al., 2016
cancer xenotransplantation Kim et al., 2020
stomach carcinoma cancer xenotransplantation Shen et al., 2020
prostate cancer cancer xenotransplantation Zoni et al., 2017
GENE EXPRESSION
Gene expression in y1Tg
RNA expression
Expressed Gene Structure Conditions Figures
amot standard conditions Fig. 6 from Zheng et al., 2009
amotl1 standard conditions Fig. 6 from Zheng et al., 2009
apela control Fig. 3 with image from Helker et al., 2015
apln amputation: fin, hypoxia, chemical treatment: cobalt dichloride Fig. 5 from Eyries et al., 2008
aplnra amputation: fin, hypoxia, chemical treatment: cobalt dichloride Fig. 5 from Eyries et al., 2008
aplnrb amputation: fin, hypoxia, chemical treatment: cobalt dichloride Fig. 5 from Eyries et al., 2008
bmp2b standard conditions Fig. 7 with image from Swartz et al., 2011
bmp4 standard conditions Fig. 7 with image from Swartz et al., 2011
brpf1 standard conditions Fig. 3 with image from Laue et al., 2008
cahz standard conditions 2 with image from Greenhough et al., 2018
hypoxia 2 with image from Greenhough et al., 2018
cdh5 standard conditions 10 figures with image from 8 publications
col22a1 standard conditions Fig. 2 with image from Ton et al., 2018
Fig. 3 with image from Huang et al., 2009
ctsk control Fig. 5 with image from Petrey et al., 2012
cttnl standard conditions Fig. S7 from Kaluza et al., 2011
cyp1a chemical treatment: pharmaceutical Fig. 2Fig. 3 from Incardona et al., 2011
dab2 control Fig. 6 from Cermenati et al., 2013
Fig. 8 from Zou et al., 2011
dlc standard conditions Fig. S8 from Kobayashi et al., 2014
dld standard conditions Fig. S8 from Kobayashi et al., 2014
dll4 chemical treatment by environment: environmental contaminant, amputation: caudal fin Fig. 2 from Baek et al., 2017
dock1 standard conditions Fig. 2 from Epting et al., 2010
dre-mir-30b standard conditions Fig. S1 from Jiang et al., 2013
dre-mir-30c standard conditions Fig. S1 from Jiang et al., 2013
drl standard conditions Fig. 3 with image from Kobayashi et al., 2019
Fig. 1 with image from Pimtong et al., 2014
drll.1 standard conditions Fig. 1 with image from Pimtong et al., 2014
drll.2 standard conditions Fig. 1 with image from Pimtong et al., 2014
drll.3 standard conditions Fig. 1 with image from Pimtong et al., 2014
dusp6 standard conditions Fig. 1 with image from Missinato et al., 2018
resection: cardiac ventricle Fig. 1 with image from Missinato et al., 2018
efnb2a control Fig. 1Fig. 6 from Esser et al., 2018
Fig. 1 from Aranguren et al., 2011
chemical treatment by environment: DMH1 Fig. 6 from Esser et al., 2018
egfl7 control Fig. 8 from Zou et al., 2011
egr1 physical alteration: anatomical structure Fig. 7 with imageFig. 8 with image from Huang et al., 2008
elnb standard conditions Fig. 3 from Faucherre et al., 2020
epas1b standard conditions Fig. 3 with image from Rojas et al., 2007
ephb2a control Fig. S9 from Cvejic et al., 2011
ephb4a control Fig. 2Fig. 6 from Esser et al., 2018
Fig. 1 from Aranguren et al., 2011
chemical treatment by environment: DMH1 Fig. 6 from Esser et al., 2018
etsrp control Fig. 3 from Baltrunaite et al., 2017
cancer xenotransplantation Fig. 3 from Baltrunaite et al., 2017
fgf10a standard conditions Fig. 7 with image from Swartz et al., 2011
fgfr1a control Fig. 1 with image from De Smet et al., 2014
fgfr2 control Fig. 1 with image from De Smet et al., 2014
fgfr3 control Fig. 1 with image from De Smet et al., 2014
fgfr4 control Fig. 1 with image from De Smet et al., 2014
fli1 standard conditions Fig. 5 with image from Eve et al., 2017
Fig. S5 with image from Wakayama et al., 2015
Fig. 4 with image from Oehlers et al., 2011
Fig. 6 from Cermenati et al., 2008
Fig. 6Fig. 7 from Cirone et al., 2008
Fig. 6 from Potente et al., 2007
chemical treatment: O-(chloroacetylcarbamoyl)fumagillol Fig. 4 with image from Oehlers et al., 2011
Fig. 7 from Cirone et al., 2008
fli1rs control Fig. 3 from Baltrunaite et al., 2017
cancer xenotransplantation Fig. 3 from Baltrunaite et al., 2017
flt4 control Fig. 6 from Cermenati et al., 2013
Fig. 1 from Aranguren et al., 2011
fmnl1b standard conditions Fig. S5 with image from Wakayama et al., 2015
fmnl2a standard conditions Fig. S5 with image from Wakayama et al., 2015
fmnl2b standard conditions Fig. S5 with image from Wakayama et al., 2015
fmnl3 standard conditions Fig. S5 with image from Wakayama et al., 2015
gata1a standard conditions Fig. 5 with image from Eve et al., 2017
Fig. 2 from Hart et al., 2007
gipc1 standard conditions Fig. S1 from Chittenden et al., 2006
Fig. 4 from Wang et al., 2006
gnat2 control Fig. 2 from Alvarez et al., 2010
chemical treatment: glucose Fig. 2 from Alvarez et al., 2010
gpr182 standard conditions Fig. 1 with image from Kwon et al., 2020
gpr183a control Fig. S3 with image from Zhang et al., 2015
gprc5ba standard conditions 2 with image from Greenhough et al., 2018
hypoxia 2 with image from Greenhough et al., 2018
gprc5bb standard conditions 2 with image from Greenhough et al., 2018
hypoxia 2 with image from Greenhough et al., 2018
gprc5c standard conditions 2 with image from Greenhough et al., 2018
hypoxia 2 with image from Greenhough et al., 2018
hbae1.1 control Fig. 2 with image from Jin et al., 2009
hbbe1.1 standard conditions Fig. 5 with image from Eve et al., 2017
hey2 control Fig. 1 from Aranguren et al., 2011
chemical treatment by environment: environmental contaminant, amputation: caudal fin Fig. 2 from Baek et al., 2017
hif1ab standard conditions Fig. 2 with image from Rojas et al., 2007
hmgb1a control Fig. 4 from Fang et al., 2014
physical alteration: spinal cord Fig. 4 from Fang et al., 2014
hsd3b standard conditions Fig. 2 with imageFig. 6 with imageFig. 7 with image from Liu et al., 2006
icam3 standard conditions Fig. 1 with image from Hsieh et al., 2018
igfbp7 standard conditions Fig. 4 from Hooper et al., 2009
isl2a standard conditions Fig. S1 from Chittenden et al., 2006
jag1a chemical treatment by environment: environmental contaminant, amputation: caudal fin Fig. 2 from Baek et al., 2017
jag2b chemical treatment by environment: environmental contaminant, amputation: caudal fin Fig. 2 from Baek et al., 2017
jam2a standard conditions Fig. 3 from Kobayashi et al., 2014
jam3b standard conditions Fig. S1 from Kobayashi et al., 2019
jarid2a standard conditions Fig. 5 with image from Singh et al., 2017
junba standard conditions Fig. 2 with image from Kiesow et al., 2015
junbb standard conditions Fig. 2 with image from Kiesow et al., 2015
kdrl standard conditions Fig. 4 with image from Ward et al., 2019
Fig. 3 from Baltrunaite et al., 2017
Fig. 4 with image from Singh et al., 2017
Fig. 2 with image from Kiesow et al., 2015
Fig. 8 from Zou et al., 2011
chemical treatment: vascular endothelial growth factor receptor antagonist Fig. 4 with image from Monteiro et al., 2016
cancer xenotransplantation Fig. 3 from Baltrunaite et al., 2017
klf2a control Fig. 4 from Jiménez-Amilburu et al., 2015
lcp1 control Fig. 4 with image from Jin et al., 2009
lhx6a standard conditions Fig. 5 with image from Swartz et al., 2011
lmo2 resection: caudal fin Fig. 5 from Meng et al., 2016
lrrc15 standard conditions Fig. 3 with image from Kobayashi et al., 2019
lyve1b control Fig. 6 from Cermenati et al., 2013
mcamb control Fig. 4 from Liu et al., 2016
transection: spinal cord Fig. 4 from Liu et al., 2016
meox1 standard conditions Fig. 2 from Nguyen et al., 2014
mir30a standard conditions Fig. S1 from Jiang et al., 2013
mir30d standard conditions Fig. S1 from Jiang et al., 2013
mir30e-2 standard conditions Fig. S1 from Jiang et al., 2013
mir126a standard conditions Fig. 4 from Zou et al., 2011
mir126b standard conditions Fig. 4 from Zou et al., 2011
mlc1 standard conditions Fig. 4 from Sirisi et al., 2014
msx1a standard conditions Fig. 5 with image from Swartz et al., 2011
mthfd2 chemical treatment by injection: oxidised phospholipid Fig. 6 from Hitzel et al., 2018
myb standard conditions Fig. 1Fig. 3Fig. 6 from Jin et al., 2007
myod1 standard conditions Fig. 5 with image from Eve et al., 2017
ncor2 standard conditions Fig. 1 from Wei et al., 2014
nostrin control Fig. 1 from Kovacevic et al., 2012
notch1b chemical treatment by environment: environmental contaminant, amputation: caudal fin Fig. 2 from Baek et al., 2017
notch3 standard conditions Fig. 2 with image from Wang et al., 2014
npas4a standard conditions Fig. 7 from Esser et al., 2017
ntn1a control Fig. 3text only from Wilson et al., 2006
ntn4 control Fig. 1Fig. S1 from Lambert et al., 2012
osr1 standard conditions Fig. 5 with image from Swartz et al., 2011
osr2 standard conditions Fig. 5 with image from Swartz et al., 2011
pak1 control Fig. 8 from Zou et al., 2011
pax2a control Fig. 2 from Hart et al., 2007
pax9 standard conditions Fig. 5 with image from Swartz et al., 2011
pcna standard conditions Fig. 2 from Leung et al., 2005
pdgfrb standard conditions Fig. 5 with image from McCarthy et al., 2016
Fig. 2 with image from Kok et al., 2015
Fig. 1 with imageFig. 2 with imageFig. 4 with imageFig. 6 with imageFig. S1 with image from Wang et al., 2014
phkg1a standard conditions Fig. S8 from Camus et al., 2012
piezo2a.2 standard conditions Fig. 1 from Faucherre et al., 2020
plod1a standard conditions 2 with image from Greenhough et al., 2018
hypoxia 2 with image from Greenhough et al., 2018
podxl2 standard conditions Fig. 6 with image from Sauteur et al., 2017
Fig. 8 from Hayashi et al., 2013
prox1a control Fig. 2 from Aranguren et al., 2011
ptger3 standard conditions Fig. 1 from Chen et al., 2017
pth1r standard conditions Fig. 1 from Gray et al., 2013
rag1 standard conditions Fig. S7 from Cvejic et al., 2011
Fig. 1Fig. 2Fig. 5 from Jin et al., 2007
reck standard conditions Fig. 5 with image from Ulrich et al., 2016
robo4 standard conditions Fig. S1 from Chittenden et al., 2006
runx1 standard conditions Fig. 5 with image from Eve et al., 2017
s1pr1 standard conditions Fig. 2 from Mendelson et al., 2013
Fig. 4 with image from Ben Shoham et al., 2012
s1pr2 standard conditions Fig. 2 from Mendelson et al., 2013
s1pr3a standard conditions Fig. 2 from Mendelson et al., 2013
sec14l8 standard conditions Fig. 1 with image from Gong et al., 2019
sema3aa control Fig. 4 with image from Ward et al., 2019
sema3ab control Fig. 4 with image from Ward et al., 2019
sema3fa control Fig. 4 with image from Ward et al., 2019
sema3fb control Fig. 4 with image from Ward et al., 2019
shha standard conditions Fig. 7 with image from Swartz et al., 2011
sirt1 standard conditions Fig. 4 from Potente et al., 2007
spi1b standard conditions Fig. 5 with image from Eve et al., 2017
syt2a standard conditions Fig. 2 with image from Kiesow et al., 2015
tal1 standard conditions Fig. 5 with image from Eve et al., 2017
tcf7l2 standard conditions Fig. 2 with image from Facchinello et al., 2017
tek resection: caudal fin Fig. 5 from Meng et al., 2016
tg control Fig. 7 from Opitz et al., 2011
tgfb1a chemical treatment: vascular endothelial growth factor receptor antagonist Fig. 4 with image from Monteiro et al., 2016
tgfb1b chemical treatment: vascular endothelial growth factor receptor antagonist Fig. 4 with image from Monteiro et al., 2016
tgfb2 standard conditions Fig. 7 with image from Swartz et al., 2011
tgfb3 standard conditions Fig. 7 with image from Swartz et al., 2011
tgfbr3 control Fig. 3 with imageFig. 5 with image from Kamaid et al., 2015
thsd7aa standard conditions Fig. 5 with image from Wang et al., 2011
tjp1a control Fig. 2 from Alvarez et al., 2010
chemical treatment by gavage: bexarotene, chemical treatment by injection: doxorubicin Fig. 6 from Ma et al., 2020
Fig. 2 from Alvarez et al., 2010
tjp1b chemical treatment by gavage: bexarotene, chemical treatment by injection: doxorubicin Fig. 6 from Ma et al., 2020
tln1 standard conditions Fig. 5 with image from James et al., 2016
tmem88a standard conditions Fig. 3 from Eve et al., 2017
tmem88b standard conditions Fig. 7 with image from Eve et al., 2017
tmem184a standard conditions Fig. 1 with image from Farwell et al., 2017
amputation: caudal fin Fig. 1 with image from Farwell et al., 2017
tp53 control Fig. 4 with image from Espín et al., 2013
vegfaa standard conditions Fig. 4 with image from Ward et al., 2019
Fig. 5Fig. 7 with image from Shi et al., 2014
Fig. 6 with image from Xu et al., 2012
Fig. 2 from Alvarez et al., 2010
chemical treatment: glucose Fig. 2 from Alvarez et al., 2010
vegfab control Fig. 4 with image from Ward et al., 2019
Fig. 4 with image from Oehlers et al., 2011
chemical treatment: pharmaceutical Fig. 4 with image from Oehlers et al., 2011
vegfc control Fig. 4 with image from Ward et al., 2019
Protein expression
Antibody Antigen Genes Structure Conditions Figures
Ab1-hoxc9 standard conditions Fig. S6 from Stoll et al., 2011
Ab2-plcg1 standard conditions Fig. S1 with image from Shin et al., 2016
Ab1-mef2 resection: cardiac ventricle Fig. 5 with image from Missinato et al., 2018
Fig. 3Fig. 4 from Missinato et al., 2015
Ab2-mapk14 standard conditions Fig. S1 with image from Shin et al., 2016
Ab3-lcp1 control Fig. 2Fig. 3 from Duy et al., 2017
Fig. 4 with image from Jin et al., 2009
Ab2-lcp1 viral treatment: Sprivirus cyprinus Fig. 1Fig. 5 from Varela et al., 2014
Ab9-mapk chemical treatment by environment: DAPT Fig. 7 with image from Shin et al., 2016
Ab1-nrp1 control Fig. 2 from Lowe et al., 2019
Ab3-smad2 standard conditions Fig. 4Fig. 5 from Flanagan-Steet et al., 2016
Ab10-prox1 standard conditions Fig. 3 with imageFig. 4 with imageFig. 7 with image from Shin et al., 2016
Ab1-col2a chemical treatment: pharmaceutical Fig. 4 with image from Ning et al., 2013
zn-8 standard conditions Fig. 2 from Lin et al., 2013
Fig. 8 with image from Huang et al., 2009
Fig. 4 from Kucenas et al., 2009
Ab4-GFP standard conditions Fig. 3 with imageFig. 4 with imageFig. 5 with imageFig. 7 with image from Yang et al., 2022
Fig. 4 with imageFig. 5 with image from James et al., 2016
Ab5-GFP standard conditions Fig. 1 with image from Farwell et al., 2017
Ab-A4.1025 standard conditions Fig. S5 from Nguyen et al., 2014
Fig. S4 with image from Hinits et al., 2012
Ab2-mapk standard conditions Fig. 2 with image from Missinato et al., 2018
Ab1-ctsk standard conditions Fig. 6 from Flanagan-Steet et al., 2016
Fig. 5 with image from Petrey et al., 2012
Ab2-cspg4 control Fig. 6 with imageFig. 7 with image from Flanagan-Steet et al., 2018
Ab7-mapk standard conditions Fig. 5 with image from Kobayashi et al., 2019
Fig. 3 with image from Christie et al., 2010
Ab1-aldh1a2 cryoablation: heart Fig. 4 with image from Marín-Juez et al., 2019
Ab3-dag1 standard conditions Fig. 3 from Wood et al., 2011
Ab1-cldn5 standard conditions Fig. 3 with image from Wang et al., 2014
Ab2-pcna standard conditions Fig. 3 from Duy et al., 2017
Fig. S8 with image from Cheng et al., 2016
Ab3-lcp1 chemical treatment by environment: pentetrazol Fig. 2Fig. 3 from Duy et al., 2017
zn-12 standard conditions Fig. 5 with image from Krueger et al., 2011
Ab5-prox1 standard conditions Fig. 4 with image from Kärpanen et al., 2017
Ab1-cav1 cryoablation: cardiac ventricle Figure 1 with image from Grivas et al., 2020
Ab2-pcna chemical treatment by environment: pentetrazol Fig. 3 from Duy et al., 2017
zrf-1 standard conditions Fig. S3 with image from Fleming et al., 2013
Ab1-abcb1/4/5 standard conditions Fig. 3 with imageFig. S2 with image from Fleming et al., 2013
Ab1-vegfc physical alteration: anatomical structure Fig. 5 with image from Khatib et al., 2010
Ab1-cav1 standard conditions Figure 1 with image from Grivas et al., 2020
zns-5 standard conditions Fig. 7 with image from Huang et al., 2009
Ab-F59 resection: cardiac ventricle Fig. 6 from Missinato et al., 2015
Ab5-GFP amputation: caudal fin Fig. 1 with image from Farwell et al., 2017
Ab-MF20 standard conditions Fig. 5 with image from Cheng et al., 2016
Ab1-plcg1 standard conditions Fig. S1 with image from Shin et al., 2016
Ab1-gipc standard conditions Fig. 1 from Hermans et al., 2010
Ab10-prox1 chemical treatment by environment: SL-327 Fig. 4 with image from Shin et al., 2016
Ab1-rprm standard conditions Fig. 3 with image from Stanic et al., 2018
znp-1 standard conditions Fig. 6 with image from Kwon et al., 2013
Ab1-tjp1 standard conditions 13 figures with image from 7 publications
Ab11-smad standard conditions Fig. 4 from Flanagan-Steet et al., 2016
zn-5 chemical treatment: glucose Fig. 4 from Alvarez et al., 2010
Ab2-cspg4 chemical treatment by environment: SB 505124 Fig. 6 with image from Flanagan-Steet et al., 2018
Ab1-nrp1 cold damage: cardiac ventricle Fig. 2 from Lowe et al., 2019
Ab1-smad standard conditions Fig. 5 with image from Li et al., 2018
Fig. 4Fig. 5 from Flanagan-Steet et al., 2016
Ab2-smad2/3 standard conditions Fig. 4 from Flanagan-Steet et al., 2016
Ab1-tmem184a amputation: caudal fin Fig. 1 with image from Farwell et al., 2017
Ab1-cdh5 chemical treatment: pharmaceutical Fig. 3 with image from De Smet et al., 2014
Ab1-esama control Fig. 5 from Sauteur et al., 2014
zpr-3 chemical treatment: glucose Fig. 4 from Alvarez et al., 2010
Ab4-h3 control Fig. 5 with image from Kara et al., 2017
Ab-T4 control Fig. 7Fig. 8 from Opitz et al., 2011
Ab1-tmem184a standard conditions Fig. 1 with image from Farwell et al., 2017
Ab1-casp3 control Fig. 6 from Craig et al., 2015
Ab1-lama1 standard conditions Fig. 4 with image from James et al., 2016
Fig. 3 from Hultin et al., 2014
Ab1-lama2 standard conditions text only from Zygmunt et al., 2011
Ab1-tjp1 chemical treatment by gavage: bexarotene, chemical treatment by injection: doxorubicin Fig. 6 from Ma et al., 2020
Fig. 5 from Sauteur et al., 2014
Ab1-dag1 standard conditions Fig. 3 from Wood et al., 2011
zpr-1 control Fig. 4Fig. 5 from Alvarez et al., 2010
Ab1-pan-Cadherin standard conditions Fig. S3 from Eberhart et al., 2008
zpr-1 chemical treatment: glucose Fig. 4Fig. 5 from Alvarez et al., 2010
zn-5 standard conditions Fig. S5 with image from Ning et al., 2013
Fig. 4 from Alvarez et al., 2010
Fig. 2 with image from Schwend et al., 2009
Ab1-col2a standard conditions Fig. 3 with imageFig. 5 with imageFig. 7 with image from Yang et al., 2022
Fig. 4 with image from Li et al., 2018
Fig. 2 with imageFig. 4 with image from Ning et al., 2013
Fig. 4 from Flanagan-Steet et al., 2009
Ab2-lcp1 control Fig. 1 from Varela et al., 2014
zpr-3 control Fig. 4 from Alvarez et al., 2010
Ab1-esama chemical treatment: pharmaceutical Fig. 5 from Sauteur et al., 2014
Ab9-mapk standard conditions Fig. 4 with image from Kärpanen et al., 2017
Fig. 1 with imageFig. 2 with imageFig. 7 with image from Shin et al., 2016
Fig. 4 with image from Shin et al., 2016
Fig. 4 with image from Le Guen et al., 2014
Fig. 8 from Yu et al., 2010
Ab1-cdh5 cdh5 standard conditions Fig. 3 with image from De Smet et al., 2014
Fig. S1 from Sauteur et al., 2014
Fig. 8 from Hayashi et al., 2013
Fig. 6 with image from Carra et al., 2012
Fig. 1 with image from Herwig et al., 2011
Fig. 7 with imageFig. 8 with image from Wang et al., 2010
Fig. 3 with imageFig. 4 with image from Blum et al., 2008
Ab1-cyp1a cyp1a chemical treatment: pharmaceutical Fig. 2Fig. 3 from Incardona et al., 2011
Ab3-GFP EGFP standard conditions Fig. 3 from Hogan et al., 2008
Ab1-GFP GFP chemical treatment: pharmaceutical Fig. 2Fig. 3 from Incardona et al., 2011
Ab1-hmgb1a hmgb1a control Fig. 4 from Fang et al., 2014
Ab1-hmgb1a physical alteration: spinal cord Fig. 4 from Fang et al., 2014
Ab1-meox1 meox1 standard conditions Fig. 2Fig. S3 from Nguyen et al., 2014
Ab1-mlc1 mlc1 standard conditions Fig. 4 from Sirisi et al., 2014
Ab1-nostrin nostrin control Fig. 1 from Kovacevic et al., 2012
Ab1-ntn4 ntn4 control Fig. 1 from Lambert et al., 2012
Ab1-pdgfrb pdgfrb standard conditions Fig. 2 with image from Kok et al., 2015
Ab1-podxl2 podxl2 standard conditions Fig. 6 with image from Sauteur et al., 2017
Fig. 3 from Hultin et al., 2014
Fig. 8 from Hayashi et al., 2013
Ab1-tg tg control Fig. 7 from Opitz et al., 2011
Ab1-tgfbr3 tgfbr3 control Fig. 3 with imageFig. 5 with image from Kamaid et al., 2015
Ab2-tmem184a tmem184a standard conditions Fig. 1 with image from Farwell et al., 2017
Ab2-tmem184a amputation: caudal fin Fig. 1 with image from Farwell et al., 2017
Ab1-tp53 tp53 control Fig. 4 with image from Espín et al., 2013
Reporter gene expression
Expressed Gene Structure Conditions Figures
EGFP standard conditions 414 figures with image from 223 publications
chemical treatment: pharmaceutical 52 figures with image from 34 publications
physical alteration: anatomical structure 73 figures with image from 46 publications
GFP standard conditions Fig. 1 with imageFig. 2 with imageFig. 7 with imageFig. S1 with image from Shin et al., 2016
Fig. 5 from Tonon et al., 2016
Fig. 2 with image from Zaucker et al., 2013
Fig. 4 with image from Murphy et al., 2010
chemical treatment: semaxanib Fig. 7 with image from Shin et al., 2016
Fig. 2Fig. 3 from Incardona et al., 2011
Fig. 3 with imageFig. 4 with imageFig. S3 with image from Murphy et al., 2010
bacterial treatment by injection: Escherichia coli Fig. 7 from Itou et al., 2017
Fig. 2 with image from Barber et al., 2016
Fig. 2 with image from Mercatali et al., 2016
Fig. 5 from Tonon et al., 2016
PHENOTYPE
Phenotype in y1Tg
Phenotype Conditions Figures
angiogenesis decreased occurrence, abnormal cancer xenotransplantation, chemical treatment by environment: cisplatin Fig. 6 from Delasoie et al., 2020
angiogenesis decreased occurrence, abnormal chemical treatment by environment: sunitinib Fig. 4 from Delasoie et al., 2020
angiogenesis disrupted, abnormal chemical treatment: butan-1-ol Fig. 7 with image from Zeng et al., 2009
angiogenesis disrupted, abnormal chemical treatment by environment: eupatilin Fig. 8 from Lee et al., 2020
angiogenesis disrupted, abnormal chemical treatment by environment: fucosterol Fig. 8 from Bae et al., 2020
angiogenesis disrupted, abnormal chemical treatment by environment: vascular endothelial growth factor receptor antagonist Fig. 1 with image from Ai et al., 2018
angiogenesis disrupted, abnormal chemical treatment by environment: ponatinib Fig. 1 with image from Ai et al., 2018
angiogenesis disrupted, abnormal chemical treatment by environment: glycyrrhetinic acid Fig. 6 from Li et al., 2019
angiogenesis disrupted, abnormal chemical treatment: LY294002 Fig. 1 with image from Alvarez et al., 2009
angiogenesis disrupted, abnormal chemical treatment: pharmaceutical Fig. 4 from Cho et al., 2013
angiogenesis increased occurrence, abnormal cancer xenotransplantation Fig. 4 from Zhao et al., 2018
angiogenesis increased occurrence, abnormal cancer xenotransplantation Fig. 1 with image from Yang et al., 2014
angiogenesis increased occurrence, abnormal cancer xenotransplantation Fig. 6 from Würth et al., 2017
angiogenesis increased occurrence, abnormal cancer xenotransplantation Fig. 1 from Baltrunaite et al., 2017
angiogenesis increased occurrence, abnormal cancer xenotransplantation Fig. 3 with image from Li et al., 2019
angiogenesis occurrence, ameliorated chemical treatment by environment: axitinib, cancer xenotransplantation Fig. 1 with image from Yang et al., 2014
angiogenesis occurrence, ameliorated chemical treatment by environment: vatalanib, cancer xenotransplantation Fig. 1 with image from Yang et al., 2014
angiogenesis occurrence, ameliorated chemical treatment by environment: sunitinib, cancer xenotransplantation Fig. 1 with image from Yang et al., 2014
angiogenesis involved in wound healing disrupted, abnormal amputation: caudal fin, chemical treatment: LY294002 Fig. 6 with image from Alvarez et al., 2009
angiogenesis involved in wound healing process quality, abnormal amputation: fin, hypoxia, chemical treatment: pharmaceutical, chemical treatment: cobalt dichloride Fig. 6 from Eyries et al., 2008
angiogenesis involved in wound healing process quality, normal amputation: fin, chemical treatment: pharmaceutical Fig. 6 from Eyries et al., 2008
angiogenic sprout decreased length, abnormal chemical treatment: pharmaceutical Fig. 4 from Cho et al., 2013
atrioventricular canal cell population proliferation decreased process quality, abnormal chemical treatment: pharmaceutical Fig. S5 from Banjo et al., 2013
atrioventricular canal cell population proliferation decreased process quality, abnormal chemical treatment: pharmaceutical Fig. S5 from Banjo et al., 2013
atrioventricular valve hypoplastic, abnormal chemical treatment by environment: ethanol Fig. 1 with image from Sarmah et al., 2016
atrioventricular valve morphology, abnormal chemical treatment by environment: ethanol Fig. 1 with image from Sarmah et al., 2016
blood circulation decreased occurrence, abnormal physical alteration: intersegmental vessel, chemical treatment by injection: agarose Fig. 1 from Choi et al., 2017
blood circulation decreased process quality, abnormal bacterial treatment by injection: Waddlia chondrophila WSU 86-1044 Fig. 4 with image from Fehr et al., 2016
blood circulation disrupted, abnormal chemical treatment: herbicide Fig. 5 with image from Kalén et al., 2009
blood island cell death increased process quality, abnormal viral treatment: Sprivirus cyprinus Fig. 2 from Varela et al., 2014
blood vasculature broken, abnormal chemical treatment: herbicide Fig. 5 with image from Kalén et al., 2009
blood vessel mcamb expression increased amount, abnormal transection: spinal cord Fig. 4 from Liu et al., 2016
blood vessel increased branchiness, abnormal chemical treatment: pharmaceutical Fig. 1Fig. 5Fig. 6 from Jörgens et al., 2015
blood vessel increased branchiness, abnormal chemical treatment: methylglyoxal Fig. 2 from Lodd et al., 2019
blood vessel increased branchiness, abnormal chemical treatment: pharmaceutical Fig. 1Fig. 5Fig. 6 from Jörgens et al., 2015
blood vessel increased branchiness, abnormal chemical treatment: pharmaceutical Fig. 1 from Jörgens et al., 2015
blood vessel malformed, abnormal chemical treatment: pharmaceutical Fig. 6 from Pruvot et al., 2014
blood vessel morphology, abnormal chemical treatment: methylglyoxal Fig. 2 from Lodd et al., 2019
blood vessel morphology, abnormal chemical treatment: pharmaceutical Fig. 3Fig. 7 from Chen et al., 2012
blood vessel morphology, abnormal chemical treatment: pharmaceutical Fig. 1Fig. 5Fig. 6 from Jörgens et al., 2015
blood vessel morphology, abnormal chemical treatment: pharmaceutical Fig. 1 from Jörgens et al., 2015
blood vessel morphology, abnormal chemical treatment: pharmaceutical Fig. 1Fig. 5Fig. 6 from Jörgens et al., 2015
blood vessel endothelial cell tgfb1b expression decreased amount, abnormal chemical treatment: vascular endothelial growth factor receptor antagonist Fig. 4 with image from Monteiro et al., 2016
blood vessel endothelial cell kdrl expression decreased amount, abnormal chemical treatment: vascular endothelial growth factor receptor antagonist Fig. 4 with image from Monteiro et al., 2016
blood vessel endothelial cell tgfb1a expression decreased amount, abnormal chemical treatment: vascular endothelial growth factor receptor antagonist Fig. 4 with image from Monteiro et al., 2016
blood vessel endothelial cell cell-cell junction decreased amount, abnormal chemical treatment: pharmaceutical Fig. 3 with image from De Smet et al., 2014
blood vessel endothelial cell filopodium decreased amount, abnormal chemical treatment by environment: zinc atom Fig. 5 from Xia et al., 2020
brain neoplastic, abnormal cancer xenotransplantation, chemical treatment: dexamethasone Fig. 3 from Eden et al., 2015
brain central nervous system tumor increased amount, abnormal cancer xenotransplantation Fig. 4 from Pudelko et al., 2018
brain central nervous system tumor neoplastic, invasive, abnormal cancer xenotransplantation Fig. 4 from Pudelko et al., 2018
brain vasculature disorganized, abnormal chemical treatment by environment: lead diacetate Fig. 5 from Roy et al., 2014
brain vasculature morphology, abnormal standard conditions FIGURE 4 with image from Han et al., 2021
branching involved in blood vessel morphogenesis process quality, normal chemical treatment: drug Fig. S2 with image from Eisa-Beygi et al., 2013
branching morphogenesis of an epithelial tube disrupted, abnormal chemical treatment: herbicide Fig. 5 with image from Kalén et al., 2009
cardiac muscle tissue regeneration decreased process quality, abnormal resection: cardiac ventricle, chemical treatment: 4-methylumbelliferone Fig. 3 from Missinato et al., 2015
cardiac muscle tissue regeneration increased rate, abnormal chemical treatment by injection: (2E)-2-benzylidene-3-(cyclohexylamino)indan-1-one, resection: cardiac ventricle Fig. 5 with image from Missinato et al., 2018
cardiac muscle tissue regeneration increased rate, abnormal chemical treatment by injection: BCI-215, resection: cardiac ventricle Fig. 5 with image from Missinato et al., 2018
caudal artery morphology, normal standard conditions Fig. 4 with image from Liu et al., 2008
caudal fin morphology, abnormal chemical treatment by environment: Fadrozole hydrochloride Fig. 4 from Alharthy et al., 2017
caudal fin morphology, abnormal chemical treatment by environment: benzo[a]pyrene Fig. 4 from Alharthy et al., 2017
caudal fin morphology, ameliorated chemical treatment by environment: Fadrozole hydrochloride, chemical treatment by environment: 17beta-estradiol Fig. 4 from Alharthy et al., 2017
caudal fin morphology, exacerbated chemical treatment by environment: benzo[a]pyrene, chemical treatment by environment: 17beta-estradiol Fig. 4 from Alharthy et al., 2017
caudal fin vasculature blood vessel endothelial cell disorganized, abnormal chemical treatment by diet: cholesterol Fig. 2 from Yan et al., 2018
caudal fin vasculature blood vessel endothelial cell increased permeability, abnormal chemical treatment by diet: cholesterol Fig. 2 from Yan et al., 2018
caudal fin vasculature blood vessel endothelial cell morphology, abnormal chemical treatment by diet: cholesterol Fig. 2 from Yan et al., 2018
caudal fin vasculature blood vessel endothelial cell thickness, abnormal chemical treatment by diet: cholesterol Fig. 2 from Yan et al., 2018
caudal fin vasculature cholesteryl ester increased amount, abnormal high cholesterol Fig. 5 from Han et al., 2018
caudal hematopoietic tissue carcinoma present, abnormal cancer xenotransplantation Fig. 1 with image from Varanda et al., 2020
caudal vein morphology, normal standard conditions Fig. 4 with image from Liu et al., 2008
caudal vein blood circulation absent, abnormal chemical treatment: pharmaceutical Fig. 6 from Pruvot et al., 2014
caudal vein blood circulation absent, abnormal chemical treatment: pharmaceutical Fig. 6 from Pruvot et al., 2014
caudal vein blood circulation decreased process quality, abnormal chemical treatment: pharmaceutical Fig. 6 from Pruvot et al., 2014
caudal vein lipid amount, ameliorated chemical treatment by diet: cholesterol, chemical treatment by environment: ezetimibe Fig. 1Fig. 5 from Yan et al., 2018
caudal vein lipid increased amount, abnormal chemical treatment by diet: cholesterol Fig. 1Fig. 5 from Yan et al., 2018
caudal vein plexus decreased area, abnormal chemical treatment: SU6656 Figure 6 with image from Wisniewski et al., 2020
caudal vein plexus decreased area, abnormal chemical treatment: PP2 Figure 6 with image from Wisniewski et al., 2020
caudal vein plexus decreased width, abnormal chemical treatment: pharmaceutical Fig. 5 with image from Wakayama et al., 2015
caudal vein plexus decreased width, abnormal chemical treatment: pharmaceutical Fig. 1 with image from Wakayama et al., 2015
caudal vein plexus dilated, abnormal chemical treatment by environment: DMH1 Fig. 6 from Esser et al., 2018
caudal vein plexus ephb4a expression increased amount, abnormal chemical treatment by environment: DMH1 Fig. 6 from Esser et al., 2018
caudal vein plexus efnb2a expression increased amount, abnormal chemical treatment by environment: DMH1 Fig. 6 from Esser et al., 2018
caudal vein plexus efnb2a expression increased distribution, abnormal chemical treatment by environment: DMH1 Fig. 6 from Esser et al., 2018
caudal vein plexus ephb4a expression increased distribution, abnormal chemical treatment by environment: DMH1 Fig. 6 from Esser et al., 2018
caudal vein plexus malformed, abnormal chemical treatment: pharmaceutical Fig. 5 with image from Wakayama et al., 2015
caudal vein plexus efnb2a expression mislocalised, abnormal chemical treatment by environment: DMH1 Fig. 6 from Esser et al., 2018
caudal vein plexus morphology, abnormal chemical treatment: pharmaceutical Fig. 7 with image from Huang et al., 2008
caudal vein plexus morphology, abnormal chemical treatment: pharmaceutical Fig. 4 with image from De Smet et al., 2014
caudal vein plexus morphology, normal chemical treatment: semaxanib Fig. 9 with image from Ben Shoham et al., 2012
caudal vein plexus structure, abnormal chemical treatment: PP2 Figure 6 with image from Wisniewski et al., 2020
caudal vein plexus structure, abnormal chemical treatment: SU6656 Figure 6 with image from Wisniewski et al., 2020
caudal vein plexus blood vessel development process quality, abnormal chemical treatment: pharmaceutical Fig. 4 with image from De Smet et al., 2014
caudal vein plexus capillary decreased amount, abnormal chemical treatment by environment: zinc atom Fig. 5 from Xia et al., 2020
caudal vein plexus sprouting angiogenesis process quality, abnormal chemical treatment: pharmaceutical Fig. 1 with image from Wakayama et al., 2015
central artery absent, abnormal chemical treatment by environment: lead diacetate Fig. 5 from Roy et al., 2014
central artery decreased length, abnormal chemical treatment by environment: lead diacetate Fig. 6 from Roy et al., 2014
ceratobranchial 5 replacement tooth dissociated from pharyngeal arch 7 blood vessel, abnormal chemical treatment: semaxanib Fig. 4 from Crucke et al., 2015
ceratobranchial 5 replacement tooth odontogenesis rate, normal chemical treatment: semaxanib Fig. 2 from Crucke et al., 2015
ceratobranchial 5 replacement tooth odontogenesis variability of rate, abnormal chemical treatment: semaxanib Fig. 3 from Crucke et al., 2015
ceratohyal cartilage chondroblast disorganized, abnormal chemical treatment: pharmaceutical Fig. 4 with image from Ning et al., 2013
ceratohyal cartilage chondrocyte differentiation process quality, abnormal chemical treatment: pharmaceutical Fig. 4 with image from Ning et al., 2013
chondrocyte Ab2-cspg4 labeling decreased amount, abnormal chemical treatment by environment: SB 505124 Fig. 6 with image from Flanagan-Steet et al., 2018
cranial blood vessel has normal numbers of parts of type primordial hindbrain channel, normal control Fig. 2 with image from Cohen et al., 2020
dorsal aorta broken, abnormal chemical treatment by environment: ethanol Fig. 3 with image from Li et al., 2016
dorsal aorta decreased width, abnormal chemical treatment by environment: ethanol Fig. 2 with image from Li et al., 2016
dorsal aorta morphology, abnormal chemical treatment by environment: fucoidan Figure 8 with image from Bae et al., 2020
dorsal aorta morphology, abnormal chemical treatment by environment: eupatilin Fig. 8 from Lee et al., 2020
dorsal aorta morphology, normal standard conditions Fig. 4 with image from Liu et al., 2008
dorsal aorta blood vessel endothelial cell decreased length, abnormal chemical treatment: blebbistatin Fig. 8 from Hultin et al., 2014
dorsal aorta blood vessel lumenization decreased process quality, abnormal chemical treatment: blebbistatin Fig. 8 from Hultin et al., 2014
dorsal aorta endothelial cell morphogenesis decreased process quality, abnormal chemical treatment: blebbistatin Fig. 8 from Hultin et al., 2014
dorsal aorta lipid amount, ameliorated chemical treatment by diet: cholesterol, chemical treatment by environment: ezetimibe Fig. 1Fig. 5 from Yan et al., 2018
dorsal aorta lipid increased amount, abnormal chemical treatment by diet: cholesterol Fig. 1Fig. 5 from Yan et al., 2018
dorsal aorta morphogenesis decreased process quality, abnormal chemical treatment: blebbistatin Fig. 8 from Hultin et al., 2014
dorsal longitudinal anastomotic vessel aplastic, abnormal chemical treatment: pharmaceutical Fig. 5 from Lee et al., 2014
dorsal longitudinal anastomotic vessel aplastic, abnormal chemical treatment: pharmaceutical Fig. 1 from Lee et al., 2014
dorsal longitudinal anastomotic vessel aplastic, abnormal chemical treatment: pharmaceutical Fig. 1 from Lee et al., 2014
dorsal longitudinal anastomotic vessel constricted, abnormal chemical treatment by environment: diacetylmonoxime Fig. 7 with image from Nakajima et al., 2017
dorsal longitudinal anastomotic vessel disassembled, abnormal chemical treatment: pharmaceutical Fig. 2 with image from De Smet et al., 2014
dorsal longitudinal anastomotic vessel hypoplastic, abnormal chemical treatment: antagonist Fig. 1 from Chen et al., 2017
dorsal longitudinal anastomotic vessel malformed, abnormal chemical treatment by environment: SKF-96365 hydrochloride Fig. 7 with image from Savage et al., 2019
dorsal longitudinal anastomotic vessel morphology, abnormal chemical treatment by environment: diacetylmonoxime Fig. 7 with image from Nakajima et al., 2017
dorsal longitudinal anastomotic vessel morphology, abnormal chemical treatment by environment: fucoidan Figure 8 with image from Bae et al., 2020
dorsal longitudinal anastomotic vessel morphology, abnormal chemical treatment by environment: eupatilin Fig. 8 from Lee et al., 2020
dorsal longitudinal anastomotic vessel split, abnormal chemical treatment by environment: SKF-96365 hydrochloride Fig. 7 with image from Savage et al., 2019
dorsal longitudinal anastomotic vessel truncated, abnormal chemical treatment by environment: semaxanib Fig. 3 from Carretero-Ortega et al., 2019
dorsal longitudinal anastomotic vessel blood circulation absent, abnormal chemical treatment: pharmaceutical Fig. 6 from Pruvot et al., 2014
dorsal longitudinal anastomotic vessel blood circulation absent, abnormal chemical treatment: pharmaceutical Fig. 6 from Pruvot et al., 2014
dorsal longitudinal anastomotic vessel endothelial cell detached from dorsal longitudinal anastomotic vessel endothelial cell, abnormal chemical treatment: pharmaceutical Fig. 2 with image from De Smet et al., 2014
dorsal longitudinal anastomotic vessel sprouting angiogenesis decreased occurrence, abnormal chemical treatment by environment: SKF-96365 hydrochloride Fig. 7 with image from Savage et al., 2019
embryonic pectoral fin morphogenesis process quality, abnormal chemical treatment: thalidomide Fig. S18 from Ito et al., 2010
endocardial cushion aplastic, abnormal chemical treatment: pharmaceutical Fig. 4 from Banjo et al., 2013
endocardium cell decreased amount, abnormal chemical treatment by environment: ethanol Fig. 5 with image from Sarmah et al., 2017
endothelial cell tjp1a expression increased amount, abnormal chemical treatment by gavage: bexarotene, chemical treatment by injection: doxorubicin Fig. 6 from Ma et al., 2020
endothelial cell tjp1a expression increased amount, abnormal chemical treatment by gavage: isotretinoin, chemical treatment by injection: doxorubicin Fig. 6 from Ma et al., 2020
endothelial cell tjp1b expression increased amount, abnormal chemical treatment by gavage: bexarotene, chemical treatment by injection: doxorubicin Fig. 6 from Ma et al., 2020
endothelial cell cell-cell junction ab1-tjp1 labeling spatial pattern, abnormal chemical treatment by injection: doxorubicin Fig. 6 from Ma et al., 2020
endothelial cell cell-cell junction ab1-tjp1 labeling spatial pattern, ameliorated chemical treatment by gavage: bexarotene, chemical treatment by injection: doxorubicin Fig. 6 from Ma et al., 2020
endothelial cell cell-cell junction ab1-tjp1 labeling spatial pattern, ameliorated chemical treatment by gavage: isotretinoin, chemical treatment by injection: doxorubicin Fig. 6 from Ma et al., 2020
epithelial cell protruding, abnormal bacterial treatment by injection: Escherichia coli Fig. 2 with image from Barber et al., 2016
eye decreased size, abnormal chemical treatment by environment: Fadrozole hydrochloride, chemical treatment by environment: 17beta-estradiol Fig. 3 from Alharthy et al., 2017
eye decreased size, abnormal chemical treatment by environment: 17beta-estradiol Fig. 3 from Alharthy et al., 2017
eye decreased size, abnormal chemical treatment by environment: benzo[a]pyrene, chemical treatment by environment: 17beta-estradiol Fig. 3 from Alharthy et al., 2017
eye decreased size, abnormal chemical treatment by environment: benzo[a]pyrene Fig. 3 from Alharthy et al., 2017
eye decreased size, abnormal chemical treatment by environment: Fadrozole hydrochloride Fig. 3 from Alharthy et al., 2017
eye carcinoma decreased size, ameliorated cancer xenotransplantation, chemical treatment by environment: quininib Figure 10 with image from Slater et al., 2020
eye carcinoma decreased size, ameliorated chemical treatment by environment: montelukast, cancer xenotransplantation Figure 10 with image from Slater et al., 2020
eye carcinoma present, abnormal cancer xenotransplantation Figure 10 with image from Slater et al., 2020
fin regeneration disrupted, abnormal chemical treatment by injection: heparin, amputation: caudal fin Fig. 7 from Farwell et al., 2017
gut angiogenesis decreased occurrence, abnormal chemical treatment by injection: docosahexaenoic acid Fig. 4 with image from Wang et al., 2016
gut blood vasculature decreased branchiness, abnormal chemical treatment by injection: docosahexaenoic acid Fig. 4 with image from Wang et al., 2016
hatching decreased occurrence, abnormal chemical treatment by environment: benzo[a]pyrene, chemical treatment by environment: 17beta-estradiol Fig. 2 from Alharthy et al., 2017
hatching decreased occurrence, abnormal chemical treatment by environment: Fadrozole hydrochloride Fig. 2 from Alharthy et al., 2017
hatching decreased occurrence, abnormal chemical treatment by environment: benzo[a]pyrene Fig. 2 from Alharthy et al., 2017
hatching decreased occurrence, abnormal chemical treatment by environment: Fadrozole hydrochloride, chemical treatment by environment: 17beta-estradiol Fig. 2 from Alharthy et al., 2017
heart straight, abnormal chemical treatment by environment: ethanol Fig. 1 with image from Sarmah et al., 2016
heart contraction arrested, abnormal chemical treatment by environment: diacetylmonoxime Fig. 7 with image from Nakajima et al., 2017
heart contraction increased rate, abnormal chemical treatment by environment: ethanol Fig. 1 with image from Sarmah et al., 2016
heart valve development disrupted, abnormal chemical treatment: pharmaceutical Fig. 4 from Banjo et al., 2013
hyaloid vessel branchiness, abnormal chemical treatment: LY294002 Fig. 5 with image from Alvarez et al., 2009
hyaloid vessel decreased branchiness, abnormal chemical treatment: SH-11037 Fig. 2 with image from Sulaiman et al., 2016
hyaloid vessel irregular spatial pattern, abnormal chemical treatment: LY294002 Fig. 1 with imageFig. 4 with image from Alvarez et al., 2009
hyaloid vessel irregular spatial pattern, abnormal chemical treatment: EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor Fig. 4 with image from Alvarez et al., 2009
hyaloid vessel angiogenesis decreased occurrence, abnormal chemical treatment by environment: sunitinib Fig. 4 with image from Ward et al., 2019
hyaloid vessel angiogenesis decreased occurrence, abnormal chemical treatment: SH-11037 Fig. 2 with image from Sulaiman et al., 2016
hyaloid vessel sprouting angiogenesis decreased process quality, abnormal chemical treatment: pharmaceutical Fig. 5 with image from Sasore et al., 2014
hyaloid vessel sprouting angiogenesis decreased process quality, abnormal chemical treatment: pharmaceutical Fig. 5 with image from Sasore et al., 2014
hyaloid vessel sprouting angiogenesis decreased process quality, abnormal chemical treatment: pharmaceutical Fig. 5 with image from Sasore et al., 2014
hyaloid vessel sprouting angiogenesis decreased process quality, abnormal chemical treatment: pharmaceutical Fig. 5 with image from Sasore et al., 2014
hyaloid vessel sprouting angiogenesis decreased process quality, abnormal chemical treatment: pharmaceutical Fig. 5 with image from Sasore et al., 2014
hyaloid vessel sprouting angiogenesis decreased process quality, abnormal chemical treatment: pharmaceutical Fig. 5 with image from Sasore et al., 2014
hyaloid vessel sprouting angiogenesis decreased process quality, abnormal chemical treatment: pharmaceutical Fig. 5 with image from Sasore et al., 2014
intersegmental artery absent, abnormal angiogenesis inhibitor: anti-angiogenic agent Fig. 4 from Venkateswaran et al., 2014
intersegmental artery decreased width, abnormal chemical treatment by environment: ethanol Fig. 2 with image from Li et al., 2016
intersegmental artery morphology, abnormal chemical treatment by environment: ethanol Fig. 3 with image from Li et al., 2016
intersegmental vein absent, abnormal angiogenesis inhibitor: anti-angiogenic agent Fig. 4 from Venkateswaran et al., 2014
intersegmental vessel aplastic, abnormal chemical treatment: vascular endothelial growth factor receptor antagonist Fig. 4 with image from Monteiro et al., 2016
intersegmental vessel aplastic, abnormal chemical treatment: wortmannin Fig. S8 with image from Liu et al., 2008
intersegmental vessel aplastic, abnormal chemical treatment: U0126 Fig. S8 with image from Liu et al., 2008
intersegmental vessel brochidodromous, abnormal chemical treatment: wortmannin Fig. S8 with image from Liu et al., 2008
intersegmental vessel brochidodromous, abnormal chemical treatment: U0126 Fig. S8 with image from Liu et al., 2008
intersegmental vessel collapsed, abnormal chemical treatment: pharmaceutical Fig. 2 with image from De Smet et al., 2014
intersegmental vessel decreased functionality, abnormal chemical treatment: herbicide Fig. 5 with image from Kalén et al., 2009
intersegmental vessel decreased length, abnormal chemical treatment by environment: SKF-96365 hydrochloride Fig. 7 with image from Savage et al., 2019
intersegmental vessel decreased length, abnormal chemical treatment by environment: ponatinib Fig. 1 with image from Ai et al., 2018
intersegmental vessel decreased length, abnormal chemical treatment: pharmaceutical Fig. 4 from Cho et al., 2013
intersegmental vessel decreased size, abnormal chemical treatment by environment: ponatinib Fig. 1 with image from Ai et al., 2018
intersegmental vessel disassembled, abnormal chemical treatment: pharmaceutical Fig. 2 with image from De Smet et al., 2014
intersegmental vessel disorganized, abnormal chemical treatment: wortmannin Fig. S8 with image from Liu et al., 2008
intersegmental vessel disorganized, abnormal chemical treatment: U0126 Fig. S8 with image from Liu et al., 2008
intersegmental vessel disorganized, abnormal chemical treatment: DAPT Fig. 4 with image from Jensen et al., 2012
intersegmental vessel has extra parts of type vascular sprouts, abnormal chemical treatment: DAPT Fig. 4 with image from Jensen et al., 2012
intersegmental vessel has extra parts of type blood vessel, abnormal chemical treatment: DAPT Fig. 4 with image from Jensen et al., 2012
intersegmental vessel hypoplastic, abnormal chemical treatment: antagonist Fig. 1 from Chen et al., 2017
intersegmental vessel hypoplastic, abnormal chemical treatment by environment: glycyrrhetinic acid Fig. 6 from Li et al., 2019
intersegmental vessel immature, abnormal chemical treatment by environment: semaxanib Fig. S10 with image from Fu et al., 2017
intersegmental vessel immature, abnormal chemical treatment: semaxanib Fig. 1 from Crucke et al., 2015
intersegmental vessel increased branchiness, abnormal chemical treatment by injection: oxidised phospholipid Fig. 6 from Hitzel et al., 2018
intersegmental vessel increased mass density, abnormal chemical treatment: DAPT Fig. 4 with image from Jensen et al., 2012
intersegmental vessel malformed, abnormal chemical treatment: pharmaceutical Fig. 1 from Lee et al., 2014
intersegmental vessel malformed, abnormal chemical treatment: pharmaceutical Fig. 5 from Lee et al., 2014
intersegmental vessel malformed, abnormal chemical treatment: pharmaceutical Fig. 1 from Lee et al., 2014
intersegmental vessel morphology, abnormal chemical treatment by environment: fucoidan Figure 8 with image from Bae et al., 2020
intersegmental vessel morphology, abnormal radiation Fig. 5Fig. 6Fig. 7 from Dong et al., 2008
intersegmental vessel morphology, abnormal chemical treatment: pharmaceutical Fig. 1Fig. 5Fig. 6 from Jörgens et al., 2015
intersegmental vessel morphology, abnormal chemical treatment: methylglyoxal Fig. 2 from Lodd et al., 2019
intersegmental vessel morphology, abnormal chemical treatment: pharmaceutical Fig. 1 from Jörgens et al., 2015
intersegmental vessel morphology, abnormal chemical treatment: pharmaceutical Fig. 1Fig. 5Fig. 6 from Jörgens et al., 2015
intersegmental vessel morphology, abnormal chemical treatment: pharmaceutical Fig. 3Fig. 7 from Chen et al., 2012
intersegmental vessel morphology, abnormal chemical treatment by injection: oxidised phospholipid Fig. 6 from Hitzel et al., 2018
intersegmental vessel morphology, abnormal chemical treatment: butan-1-ol Fig. 7 with image from Zeng et al., 2009
intersegmental vessel morphology, normal standard conditions Fig. 4 with image from Liu et al., 2008
intersegmental vessel non-functional, abnormal chemical treatment by environment: glycyrrhetinic acid Fig. 6 from Li et al., 2019
intersegmental vessel normal length, normal chemical treatment by environment: NAD Fig. 2 with image from Bailey et al., 2019
intersegmental vessel shortened, abnormal constant light Fig. 1 with image from Jensen et al., 2012
intersegmental vessel structure, abnormal chemical treatment: pharmaceutical Fig. 1 from Jörgens et al., 2015
intersegmental vessel structure, abnormal chemical treatment: pharmaceutical Fig. 1Fig. 5Fig. 6 from Jörgens et al., 2015
intersegmental vessel structure, abnormal chemical treatment: pharmaceutical Fig. 1Fig. 5Fig. 6 from Jörgens et al., 2015
intersegmental vessel truncated, abnormal chemical treatment by environment: semaxanib Fig. 3 from Carretero-Ortega et al., 2019
intersegmental vessel angiogenesis disrupted, abnormal chemical treatment by environment: cabozantinib Fig. 1 from Wu et al., 2020
intersegmental vessel angiogenesis disrupted, abnormal chemical treatment by environment: regorafenib Fig. 1 from Wu et al., 2020
intersegmental vessel blood circulation absent, abnormal chemical treatment: pharmaceutical Fig. 6 from Pruvot et al., 2014
intersegmental vessel blood circulation absent, abnormal chemical treatment: pharmaceutical Fig. 6 from Pruvot et al., 2014
intersegmental vessel blood circulation absent, abnormal chemical treatment: pharmaceutical Fig. 6 from Pruvot et al., 2014
intersegmental vessel blood vessel endothelial cell spade-shaped, abnormal chemical treatment by environment: SKF-96365 hydrochloride Fig. 7 with image from Savage et al., 2019
intersegmental vessel carcinoma neoplastic, metastatic, abnormal cancer xenotransplantation Fig. 3 from Ganaie et al., 2018
intersegmental vessel cell junction morphology, abnormal chemical treatment: pharmaceutical Fig. 5 from Sauteur et al., 2014
intersegmental vessel cell junction morphology, abnormal chemical treatment: pharmaceutical Fig. 5 from Sauteur et al., 2014
intersegmental vessel endothelial cell decreased adhesivity, abnormal chemical treatment: pharmaceutical Fig. 3 with image from De Smet et al., 2014
intersegmental vessel endothelial cell detached from intersegmental vessel endothelial cell, abnormal chemical treatment: pharmaceutical Fig. 2 with image from De Smet et al., 2014
intersegmental vessel sprouting angiogenesis decreased occurrence, abnormal chemical treatment by environment: SKF-96365 hydrochloride Fig. 7 with image from Savage et al., 2019
intersegmental vessel sprouting angiogenesis decreased occurrence, abnormal chemical treatment: antagonist Fig. 1 from Chen et al., 2017
intersegmental vessel sprouting angiogenesis decreased process quality, abnormal chemical treatment: pharmaceutical Fig. 3 with image from Sasore et al., 2014
intersegmental vessel sprouting angiogenesis decreased process quality, abnormal chemical treatment: pharmaceutical Fig. 3 with image from Sasore et al., 2014
intersegmental vessel sprouting angiogenesis decreased process quality, abnormal chemical treatment: pharmaceutical Fig. 3 with image from Sasore et al., 2014
intersegmental vessel sprouting angiogenesis decreased process quality, abnormal chemical treatment: pharmaceutical Fig. 3 with image from Sasore et al., 2014
intersegmental vessel sprouting angiogenesis decreased process quality, abnormal chemical treatment: pharmaceutical Fig. 3 with image from Sasore et al., 2014
intersegmental vessel unidimensional cell growth process quality, abnormal chemical treatment: pharmaceutical Fig. 5 from Sauteur et al., 2014
intestine vasculature branchiness, abnormal chemical treatment: pharmaceutical Fig. 4 with image from Oehlers et al., 2011
intestine vasculature structure, normal chemical treatment: pharmaceutical Fig. 4 with image from Oehlers et al., 2011
lateral zone of dorsal telencephalon blood cell dilated, abnormal chemical treatment by environment: pentetrazol Fig. 2 from Duy et al., 2017
lateral zone of dorsal telencephalon leukocyte increased amount, abnormal chemical treatment by environment: pentetrazol Fig. 2 from Duy et al., 2017
liver vasculature dilated, abnormal chemical treatment: ethanol Fig. S2 from Howarth et al., 2013
lymphangiogenesis disrupted, abnormal chemical treatment: indometacin Figure 1 with image from Iwasaki et al., 2019
lymphangiogenesis disrupted, ameliorated chemical treatment: indometacin, chemical treatment: sulprostone Figure 1 with image from Iwasaki et al., 2019
lymphangiogenic sprout absent, abnormal chemical treatment by environment: SL-327 Fig. 4 with image from Shin et al., 2016
lymphangiogenic sprout Ab10-prox1 labeling absent, abnormal chemical treatment by environment: SL-327 Fig. 4 with image from Shin et al., 2016
MAPK cascade disrupted, abnormal chemical treatment: 2-(2-amino-3-methoxyphenyl)chromen-4-one Fig. 4 with image from Le Guen et al., 2014
mid cerebral vein morphology, abnormal chemical treatment by environment: lead diacetate Fig. 5 from Roy et al., 2014
motor neuron axon guidance process quality, normal chemical treatment: butan-1-ol Fig. 7 with image from Zeng et al., 2009
ocular blood vessel decreased amount, abnormal chemical treatment: EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor Fig. 4 with image from Alvarez et al., 2009
ocular blood vessel decreased amount, abnormal chemical treatment: LY294002 Fig. 1 with imageFig. 4 with imageFig. 5 with image from Alvarez et al., 2009
ocular blood vessel diameter, ameliorated chemical treatment by environment: PK-11195, chemical treatment by environment: 4-hydroxynon-2-enal Fig. 9 with image from Lou et al., 2020
ocular blood vessel immature, abnormal chemical treatment by environment: Maxacalcitol Fig. 4 from Merrigan et al., 2020
ocular blood vessel increased diameter, abnormal chemical treatment by environment: 4-hydroxynon-2-enal Fig. 9 with image from Lou et al., 2020
ocular blood vessel increased thickness, abnormal chemical treatment: glucose Fig. 1 from Alvarez et al., 2010
ocular blood vessel adherens junction increased width, abnormal chemical treatment: D-mannitol Fig. 2 from Alvarez et al., 2010
ocular blood vessel adherens junction increased width, abnormal chemical treatment: glucose Fig. 2 from Alvarez et al., 2010
ocular blood vessel basement membrane increased thickness, abnormal chemical treatment: glucose Fig. 2 from Alvarez et al., 2010
ocular blood vessel bicellular tight junction increased width, abnormal chemical treatment: glucose Fig. 2 from Alvarez et al., 2010
ocular blood vessel bicellular tight junction increased width, abnormal chemical treatment: D-mannitol Fig. 2 from Alvarez et al., 2010
ocular blood vessel sprouting angiogenesis increased occurrence, abnormal chemical treatment by environment: 4-hydroxynon-2-enal Fig. 9 with image from Lou et al., 2020
ocular blood vessel sprouting angiogenesis occurrence, ameliorated chemical treatment by environment: PK-11195, chemical treatment by environment: 4-hydroxynon-2-enal Fig. 9 with image from Lou et al., 2020
optic artery vascular endothelium increased thickness, abnormal high cholesterol, high glucose Fig. 2 with image from Wang et al., 2013
optic artery vascular endothelium thickness, ameliorated high cholesterol, high glucose, chemical treatment: metformin Fig. 2 with image from Wang et al., 2013
optic artery vascular endothelium thickness, ameliorated high cholesterol, high glucose, chemical treatment: pioglitazone Fig. 2 with image from Wang et al., 2013
optokinetic behavior occurrence, normal chemical treatment: LY294002 Fig. 8 with image from Alvarez et al., 2009
optomotor response decreased occurrence, abnormal chemical treatment by environment: sunitinib Fig. 4 with image from Ward et al., 2019
palatoquadrate cartilage chondroblast disorganized, abnormal chemical treatment: pharmaceutical Fig. 4 with image from Ning et al., 2013
palatoquadrate cartilage chondrocyte differentiation process quality, abnormal chemical treatment: pharmaceutical Fig. 4 with image from Ning et al., 2013
parachordal vessel absent, abnormal chemical treatment by environment: SL-327 Fig. 4 with image from Shin et al., 2016
parachordal vessel vasculature development decreased occurrence, abnormal chemical treatment by environment: SL-327 Fig. 4 with image from Shin et al., 2016
pectoral fin morphology, abnormal chemical treatment by environment: benzo[a]pyrene Fig. 4 from Alharthy et al., 2017
pectoral fin morphology, exacerbated chemical treatment by environment: benzo[a]pyrene, chemical treatment by environment: 17beta-estradiol Fig. 4 from Alharthy et al., 2017
pectoral fin blood vessel aplastic, abnormal chemical treatment: thalidomide Fig. S18 from Ito et al., 2010
pectoral fin bud decreased size, abnormal chemical treatment: thalidomide Fig. S18 from Ito et al., 2010
pericardium edematous, abnormal chemical treatment by environment: Fadrozole hydrochloride Fig. 3 from Alharthy et al., 2017
pericardium edematous, abnormal chemical treatment by environment: benzo[a]pyrene Fig. 3 from Alharthy et al., 2017
pericardium edematous, abnormal chemical treatment: SH-11037 Fig. 2 with image from Sulaiman et al., 2016
pericardium edematous, abnormal bacterial treatment by injection: Waddlia chondrophila WSU 86-1044 Fig. 4 with image from Fehr et al., 2016
pericardium edematous, ameliorated chemical treatment by environment: Fadrozole hydrochloride, chemical treatment by environment: 17beta-estradiol Fig. 3 from Alharthy et al., 2017
pericardium edematous, ameliorated chemical treatment by environment: benzo[a]pyrene, chemical treatment by environment: 17beta-estradiol Fig. 3 from Alharthy et al., 2017
phagocytosis process quality, normal fungal treatment by injection: Candida albicans Fig. 2 from Brothers et al., 2011
pharyngeal arch EGFP expression decreased amount, abnormal standard conditions Fig. 6 from Chen et al., 2018
pharyngeal arch cell population proliferation decreased process quality, abnormal chemical treatment: pharmaceutical Fig. 4 with image from Ning et al., 2013
post-vent region carcinoma neoplastic, metastatic, abnormal cancer xenotransplantation Fig. 3 from Ganaie et al., 2018
post-vent region neoplasm increased amount, abnormal cancer xenotransplantation Fig. 1 from Baltrunaite et al., 2017
posterior cardinal vein morphology, normal standard conditions Fig. 4 with image from Liu et al., 2008
posterior caudal vein vascular sprouts absent, abnormal chemical treatment by environment: SL-327 Fig. 4 with image from Shin et al., 2016
primary motor neuron branched, abnormal chemical treatment: butan-1-ol Fig. 7 with image from Zeng et al., 2009
primordial hindbrain channel angiogenesis normal process quality, normal control Fig. 2 with image from Cohen et al., 2020
regenerating fin lmo2 expression increased amount, abnormal resection: caudal fin Fig. 5 from Meng et al., 2016
regenerating fin tek expression increased amount, abnormal resection: caudal fin Fig. 5 from Meng et al., 2016
regenerating fin angiogenesis decreased process quality, abnormal amputation: caudal fin, chemical treatment: BGJ-398 Fig. 5 with image from De Smet et al., 2014
regenerating fin angiogenic sprout increased amount, abnormal chemical treatment by environment: cobalt dichloride, amputation: caudal fin Fig. 2 with image from Khatib et al., 2016
regenerating fin artery absent, abnormal chemical treatment by environment: cobalt dichloride, amputation: caudal fin text only from Ma et al., 2017
regenerating fin blood vessel disorganized, abnormal chemical treatment by environment: cobalt dichloride, amputation: caudal fin text only from Ma et al., 2017
regenerating fin blood vessel remodeling decreased occurrence, abnormal chemical treatment by environment: cobalt dichloride, amputation: caudal fin Fig. 2 with image from Khatib et al., 2016
regenerating fin blood vessel remodeling disrupted, abnormal chemical treatment by environment: cobalt dichloride, amputation: caudal fin text only from Ma et al., 2017
regenerating fin endothelial cell proliferation decreased occurrence, abnormal chemical treatment by injection: heparin, amputation: caudal fin Fig. 7 from Farwell et al., 2017
regenerating fin vasculature development disrupted, abnormal chemical treatment by injection: heparin, amputation: caudal fin Fig. 6 with imageFig. 7 from Farwell et al., 2017
regenerating fin vein absent, abnormal chemical treatment by environment: cobalt dichloride, amputation: caudal fin text only from Ma et al., 2017
regenerating tissue jag2b expression decreased amount, abnormal chemical treatment by environment: GI254023X, amputation: caudal fin Fig. 2 from Baek et al., 2017
regenerating tissue jag2b expression decreased amount, abnormal chemical treatment by environment: environmental contaminant, amputation: caudal fin Fig. 2 from Baek et al., 2017
regenerating tissue dll4 expression decreased amount, abnormal chemical treatment by environment: GI254023X, amputation: caudal fin Fig. 2 from Baek et al., 2017
regenerating tissue dll4 expression decreased amount, abnormal chemical treatment by environment: environmental contaminant, amputation: caudal fin Fig. 2 from Baek et al., 2017
regenerating tissue hey2 expression decreased amount, abnormal chemical treatment by environment: GI254023X, amputation: caudal fin Fig. 2 from Baek et al., 2017
regenerating tissue hey2 expression decreased amount, abnormal chemical treatment by environment: environmental contaminant, amputation: caudal fin Fig. 2 from Baek et al., 2017
regenerating tissue jag1a expression decreased amount, abnormal chemical treatment by environment: GI254023X, amputation: caudal fin Fig. 2 from Baek et al., 2017
regenerating tissue jag1a expression decreased amount, abnormal